Raymond James Financial
VTVT icon

Raymond James Financial’s vTv Therapeutics VTVT Stock Holding History

Raymond James Financial’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$15 – 6759
2025
Q2 		$15 Buy
+1
New +$18 ﹤0.01% 6934

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Raymond James Financial's VTVT Position: Q3 2025 in Review

Raymond James Financial sold out of vTv Therapeutics (VTVT) in Q3 2025, closing a stake of 1 share — an estimated $15 sold.

Raymond James Financial first reported a position in VTVT in Q2 2025 and held it in 1 quarter. The position peaked at $15 in Q2 2025. 23 funds tracked by Wall St. Rank hold VTVT as of Q3 2025.

  • Raymond James Financial reported no remaining vTv Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 1 vTv Therapeutics share in Q3 2025, an estimated $15.
  • Raymond James Financial first reported a position in vTv Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's vTv Therapeutics position peaked at $15 in Q2 2025.
  • 23 funds tracked by Wall St. Rank held vTv Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.